Chemotherapy of ovarian cancer directed by the human tumor stem cell assay

David S Alberts, H. S. George Chen, Sydney E. Salmon, Earl A. Surwit, Laurie Young, Thomas E. Moon, Frank L. Meyskens

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The human tumor stem cell assay (HTSCA) has been used to study the in vitro sensitivity rates of anticancer drugs used in the treatment of 115 patients with previously untreated and relapsing ovarian cancer. The data from these studies have identified patterns of cross resistance and residual sensitivity between these agents, and have allowed the prospective selection of single agents possessing in vitro activity for the treatment of 32 patients with relapsing disease. cis-Platinum and vinblastine were the most active agents in vitro against ovarian TCFUs from both previously untreated and relapsing patients. Prior therapy with even one drug was associated with the acquisition of resistance to several classes of compounds (e.g., melphalan resistance was almost always associated with in vitro adriamycin resistance, P>0.001). A clinical trial yielding similar data would have required nearly 450 evaluable ovarian cancer patients. In 11 of 32 patients in vitro testing predicted sensitivity to single agents: eight of these had partial remissions for a predictive accuracy of 73%. In 33 instances the HTSCA had 100% accuracy in predicting the lack of clinical response. Thus, the HTSCA for advanced ovarian cancer appears to have a similar predictive accuracy rate to the estrogen receptor assay for predicting the response to hormonal therapy for disseminated breast cancer.

Original languageEnglish (US)
Pages (from-to)279-285
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume6
Issue number3
DOIs
StatePublished - 1981

Fingerprint

Tumor Stem Cell Assay
Chemotherapy
Stem cells
Ovarian Neoplasms
Tumors
Assays
Drug Therapy
Melphalan
Vinblastine
Estrogen Receptors
Pharmaceutical Preparations
Doxorubicin
Cisplatin
Therapeutics
In Vitro Techniques
Clinical Trials
Breast Neoplasms
Testing

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Alberts, D. S., George Chen, H. S., Salmon, S. E., Surwit, E. A., Young, L., Moon, T. E., & Meyskens, F. L. (1981). Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. Cancer Chemotherapy and Pharmacology, 6(3), 279-285. https://doi.org/10.1007/BF00256981

Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. / Alberts, David S; George Chen, H. S.; Salmon, Sydney E.; Surwit, Earl A.; Young, Laurie; Moon, Thomas E.; Meyskens, Frank L.

In: Cancer Chemotherapy and Pharmacology, Vol. 6, No. 3, 1981, p. 279-285.

Research output: Contribution to journalArticle

Alberts, DS, George Chen, HS, Salmon, SE, Surwit, EA, Young, L, Moon, TE & Meyskens, FL 1981, 'Chemotherapy of ovarian cancer directed by the human tumor stem cell assay', Cancer Chemotherapy and Pharmacology, vol. 6, no. 3, pp. 279-285. https://doi.org/10.1007/BF00256981
Alberts, David S ; George Chen, H. S. ; Salmon, Sydney E. ; Surwit, Earl A. ; Young, Laurie ; Moon, Thomas E. ; Meyskens, Frank L. / Chemotherapy of ovarian cancer directed by the human tumor stem cell assay. In: Cancer Chemotherapy and Pharmacology. 1981 ; Vol. 6, No. 3. pp. 279-285.
@article{d8b08ac591694f03aaeb821f6e8d8b35,
title = "Chemotherapy of ovarian cancer directed by the human tumor stem cell assay",
abstract = "The human tumor stem cell assay (HTSCA) has been used to study the in vitro sensitivity rates of anticancer drugs used in the treatment of 115 patients with previously untreated and relapsing ovarian cancer. The data from these studies have identified patterns of cross resistance and residual sensitivity between these agents, and have allowed the prospective selection of single agents possessing in vitro activity for the treatment of 32 patients with relapsing disease. cis-Platinum and vinblastine were the most active agents in vitro against ovarian TCFUs from both previously untreated and relapsing patients. Prior therapy with even one drug was associated with the acquisition of resistance to several classes of compounds (e.g., melphalan resistance was almost always associated with in vitro adriamycin resistance, P>0.001). A clinical trial yielding similar data would have required nearly 450 evaluable ovarian cancer patients. In 11 of 32 patients in vitro testing predicted sensitivity to single agents: eight of these had partial remissions for a predictive accuracy of 73{\%}. In 33 instances the HTSCA had 100{\%} accuracy in predicting the lack of clinical response. Thus, the HTSCA for advanced ovarian cancer appears to have a similar predictive accuracy rate to the estrogen receptor assay for predicting the response to hormonal therapy for disseminated breast cancer.",
author = "Alberts, {David S} and {George Chen}, {H. S.} and Salmon, {Sydney E.} and Surwit, {Earl A.} and Laurie Young and Moon, {Thomas E.} and Meyskens, {Frank L.}",
year = "1981",
doi = "10.1007/BF00256981",
language = "English (US)",
volume = "6",
pages = "279--285",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Chemotherapy of ovarian cancer directed by the human tumor stem cell assay

AU - Alberts, David S

AU - George Chen, H. S.

AU - Salmon, Sydney E.

AU - Surwit, Earl A.

AU - Young, Laurie

AU - Moon, Thomas E.

AU - Meyskens, Frank L.

PY - 1981

Y1 - 1981

N2 - The human tumor stem cell assay (HTSCA) has been used to study the in vitro sensitivity rates of anticancer drugs used in the treatment of 115 patients with previously untreated and relapsing ovarian cancer. The data from these studies have identified patterns of cross resistance and residual sensitivity between these agents, and have allowed the prospective selection of single agents possessing in vitro activity for the treatment of 32 patients with relapsing disease. cis-Platinum and vinblastine were the most active agents in vitro against ovarian TCFUs from both previously untreated and relapsing patients. Prior therapy with even one drug was associated with the acquisition of resistance to several classes of compounds (e.g., melphalan resistance was almost always associated with in vitro adriamycin resistance, P>0.001). A clinical trial yielding similar data would have required nearly 450 evaluable ovarian cancer patients. In 11 of 32 patients in vitro testing predicted sensitivity to single agents: eight of these had partial remissions for a predictive accuracy of 73%. In 33 instances the HTSCA had 100% accuracy in predicting the lack of clinical response. Thus, the HTSCA for advanced ovarian cancer appears to have a similar predictive accuracy rate to the estrogen receptor assay for predicting the response to hormonal therapy for disseminated breast cancer.

AB - The human tumor stem cell assay (HTSCA) has been used to study the in vitro sensitivity rates of anticancer drugs used in the treatment of 115 patients with previously untreated and relapsing ovarian cancer. The data from these studies have identified patterns of cross resistance and residual sensitivity between these agents, and have allowed the prospective selection of single agents possessing in vitro activity for the treatment of 32 patients with relapsing disease. cis-Platinum and vinblastine were the most active agents in vitro against ovarian TCFUs from both previously untreated and relapsing patients. Prior therapy with even one drug was associated with the acquisition of resistance to several classes of compounds (e.g., melphalan resistance was almost always associated with in vitro adriamycin resistance, P>0.001). A clinical trial yielding similar data would have required nearly 450 evaluable ovarian cancer patients. In 11 of 32 patients in vitro testing predicted sensitivity to single agents: eight of these had partial remissions for a predictive accuracy of 73%. In 33 instances the HTSCA had 100% accuracy in predicting the lack of clinical response. Thus, the HTSCA for advanced ovarian cancer appears to have a similar predictive accuracy rate to the estrogen receptor assay for predicting the response to hormonal therapy for disseminated breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0019785744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019785744&partnerID=8YFLogxK

U2 - 10.1007/BF00256981

DO - 10.1007/BF00256981

M3 - Article

VL - 6

SP - 279

EP - 285

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -